The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.

From August 26 to 28, 2026, the Hong Kong Convention and Exhibition Centre (HKCEC) will become the epicenter of Asia’s evolving healthcare economy as MedTech World Asia 2026 opens its doors. For global investors, sovereign wealth, and clinical pioneers, this gathering marks a decisive moment in the institutionalization of healthspan technology and longevity infrastructure across APAC.